Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer

Future Science OA

Xuxu Qiao¹  Jingru Yang¹  Yaping Wang¹  Minghong Bi¹  Shanshan Zhang¹  Mingliang Deng² 

[1] 1Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province, China;2Department of Neurosurgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Province, China;

关键词: bevacizumab;    lymphocyte-to-monocyte ratio;    neutrophil-to-lymphocyte ratio;    non-small-cell lung cancer;    platelet-to-lymphocyte ratio;    systemic immune-inflammation index;   

DOI  :  10.2144/fsoa-2021-0162

来源: DOAJ

【 摘 要 】

Purpose: Inflammatory indexes, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII) and lymphocyte-to-monocyte ratio (LMR), have been confirmed as prognostic factors in multiple manigances. However, the prognostic value of these parameters in bevacizumab-treated non-small-cell lung cancer (NSCLC) is still not clear. Methods: We retrospectively studied 119 patients with advanced NSCLC who received bevacizumab treatment. The associations of pretreatment NLR, PLR, SII and LMR with progression-free survival (PFS) and overall survival (OS) were analyzed. Results & Conclusion: The median PFS and OS of patients with high baseline NLR, PLR and SII and low LMR were significantly decreased than those of patients with low baseline NLR, PLR and SII and high LMR. Multivariable analysis indicated that high baseline SII was independently related with inferior prognosis, and baseline LMR was an independent predictor for OS.

【 授权许可】

Unknown